Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells

Cancer

Volumn 106, Issue 5, 2006, Pages 1188-1196

  Morotti, Alessandro ^a   Cilioni, Daniela ^a   Messa, Francesca ^a   Arruga, Francesca ^a   Defilippi, Ilaria ^a   Carturan, Sonia ^a   Catalano, Renata ^a   Rosso, Valentina ^a   Chiarenza, Annalisa ^a   Pilatrino, Chiara ^a   Guerrasio, Angelo ^a   Taulli, Riccardo ^a   Bracco, Enrico ^a   Pautasso, Marisa ^b   Baraban, Daniela ^b   Gottardi, Enrico ^a   Saglio, Giuseppe ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Bcr Abl; Chronic myeloid leukemia; HDAC inhibitor; Imatinib; Valproate

Indexed keywords

BCR ABL PROTEIN; DNA; HISTONE H3; HISTONE H4; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN P21; VALPROIC ACID;

APOPTOSIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE REPRESSION; HUMAN; HUMAN CELL; MONONUCLEAR CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPECTROPHOTOMETRY; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES; TUMOR CELLS, CULTURED; VALPROIC ACID;

EID: 33644505789     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21725     Document Type: Article

References (38)

1. Deininger M, Goldam J, Melo J. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343-3356.
2. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451-1464.
3. Savage DG, Antman KH. Imatinib mesylate - A new oral targeted therapy. N Engl J Med. 2002;346:683-693.
4. O'Brien S, Guilhot F, Larson RA, et al. Imatinib compared with Interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
5. Weiserg E, Griffin ID. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in Bcr/Abl-transformed hematopoietic cell lines. Blood. 2000;95:3498-3505.
6. Gorre M, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by Bcr-Abl gene mutation or amplification. Science. 2001;293:876-880.
7. Von Bubnoff N, Peschel C, Duyster J. Resistance of Philadelphia- chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia. 2003;17:829-838.
8. Hochhaus A, Kreil S, Corbin A, et al. Roots of clinical resistance to STI-571 cancer therapy. Science. 2001;293:2163.
9. Druker BJ. Can we cure CML? Blood. 2004;103:2865-2866.
10. Nimmanapalli R, Bhalla K. Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571. Oncogene. 2002;21:8584-8590.
11. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell. 2003;4:13-18.
12. Melnick A, Licht JD. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr Opin Hemat. 2002;9:322-332.
13. Witt O, Sand K, Pekrun A. Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. Blood. 2000;95:2391-2396.
14. LaMontagne KR, Hannon G, Tonks NK. Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells. Proc Natl Acad Sci USA. 1998;95:14094-14099.
15. Yu C, Rahmani M, Almenara J, et al. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl + human myeloid leukemia cells. Cancer Res. 2003;63:2118-2126.
16. Nimmanapalli R, Fuino L, Stobaugh C, et al. Cotreatment with the histone deacteylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood. 2003;101:3236-3239.
17. Nimmanapalli R, Fuino L, Bali P, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 2003;63:5126-5135.
18. CIP/ WAFI. Cancer Res. 2003;63:3637-3645.
19. Phiel CJ, Zhang F, Huang EY, et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001;276:36734-36741.
20. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inducting differentiation of transformed cells. EMBO. 2001;20:6969-6978.
21. Kramer OH, Zhu P, Ostendorff HP, et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 2003;22:3411-3420.
22. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res. 2004;64:1079-1086.
23. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
24. Mahon FX, Deininger M, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96:1070-1079.
25. Muller M, Morotti A, Ponzetto C. Activation of NF-kB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol Cell Biol. 2002;22:1060-1072.
26. Carlo-Stella C, Regazzi E, Sammarelli G, et al. Effects of the tyrosine kinase inhibitor AG957 and an anti-fas receptor antibody on CD34+ chronic myelogenous leukemia progenitor cells. Blood. 1999;93:3973-3982.
27. Jaiswal S, Traver D, Miyamoto T, et al. Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. Proc Natl Acad Sci USA. 2003;100:10002-10007.
28. Cirinna M, Trotta R, Salomoni P, et al. Bcl-2 expression restores the leukemogenic potential of a Bcr/Abl mutant defective in transformation. Blood. 2000;96:3915-3921.
29. Reuther JY, Reuther GW, Cortez D, et al. A requirement for NF-kB activation in Bcr-Abl-mediated transformation. Genes Dev. 1998;12:968-981.
30. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood. 2004;104:1266-1269.
31. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA. 2004;101:540-545.
32. Ichiyama T, Okada K, Lipton JM, et al. Sodium valproate inhibits production of TNF-a and IL-6 and activation of NF-kB. Brain Res. 2000;857:246-251.
33. Dai Y, Rahmani M, Dent P, Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage; XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol. 2005;25:5429-5444.
34. Place RF, Noonan EJ, Giardina C. HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem Pharmacol. 2005;70:394-406.
35. Gao N, Dai Y, Rahmani M, et al. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol. Mol Pharmacol. 2004;66:956-963.
36. Mayo MW, Denlinger CE, Broad RM, Yeung F, Reilly ET, Shi Y, Jones DR. Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. J Biol Chem. 2003;278:18980-18989.
37. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized. RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901-1928.
38. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using "real-time" quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe Against Cancer program. Leukemia. 2003;17:2474-2486.